Table 3 Prognostic Factors for Progression-free survival
From: PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Hazard Ratio (95% CI) | P value | |
|---|---|---|
Performance (0 vs 1) | 0.74 (0.39–1.44) | 0.38 |
Number of previous chemotherapy (1 vs 2–3) | 0.67 (0.29–1.57) | 0.36 |
Sex (female vs male) | 1.27 (0.65–2.49) | 0.49 |
Age (≤48 years vs > 48 years) | 1.69 (0.86–3.30) | 0.12 |
ECOG (0–1 vs 2) | 0.74 (0.39–1.44) | 0.38 |
Grade (I vs II-III) | 1.22 (0.43–3.45) | 0.77 |
Histologic subtype (leiomyosarcoma and synovial sarcoma vs other subtypes*) | 1.17 (0.49–2.06) | 0.95 |
Locoregional disease (yes vs no) | 1.10 (0.60–2.03) | 0.75 |
Liver metastases (yes vs no) | 0.75 (0.22–2.58) | 0.65 |
PD-L1 expression (positive vs negative) | 2.77 (1.45–5.56) | 0.006 |
TIL (high vs low) | 1.41 (0.83–2.37) | 0.197 |